SA21 Feasibility Assessment of an Indirect Treatment Comparison (ITC) of Sacituzumab Govitecan (SG) Vs Trastuzumab Deruxtecan (T-DxD) in HR+/HER2– Metastatic Breast Cancer (mBC)

Saved in:
Bibliographic Details
Published in:Value in health 2023-12, Vol.26 (12), p.S545
Main Authors: Shah, A., Thaliffdeen, R., Proudman, D., Verret, W., Sjekloca, N., Campone, M.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
DOI:10.1016/j.jval.2023.09.2930